Randomized Clinical Trial (RCT)
Randomized Controlled Trial · Also known as: RCT, randomized controlled trial, randomised controlled trial, clinical randomized trial
A randomized clinical trial (RCT) is an experimental study design in which participants are randomly assigned to an intervention group or a control group, then followed prospectively to compare outcomes. Random allocation is the defining feature: it distributes known and unknown confounders across groups by chance, making the RCT the strongest individual study design for establishing causal efficacy of a treatment or intervention under controlled conditions.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+21 more
When to use it
Use an RCT when you need to establish whether an intervention causes an improvement in outcomes — for drug approval, device evaluation, surgical technique comparison, or behavioural intervention testing. It is the appropriate design when randomisation is ethically feasible, when there is genuine clinical equipoise, and when the research question is specific enough to be answered by a defined protocol. Do NOT use an RCT when the exposure cannot be randomly assigned (e.g., genetic traits, smoking history), when the condition is too rare to recruit sufficient participants, when long latency between exposure and outcome makes follow-up impractical, or when withholding a proven effective treatment from a control group would be unethical. Observational designs (cohort, case-control) are more appropriate in those scenarios.
Strengths & limitations
- Random allocation controls for both measured and unmeasured confounding, providing the strongest evidence for causality of any individual study design.
- Pre-registration and prospective protocols reduce researcher degrees of freedom and selective reporting.
- Blinding reduces performance, placebo, and ascertainment bias when feasible.
- Regulatory bodies (FDA, EMA) accept well-conducted RCTs as the primary evidence basis for drug and device approval.
- Results from multiple RCTs can be pooled in systematic reviews and meta-analyses to increase precision.
- Strict eligibility criteria and controlled settings produce highly selected samples that may not represent routine clinical populations, limiting external validity.
- Expensive, time-consuming, and logistically complex — particularly for long-term outcomes or rare diseases.
- Ethical constraints prevent randomisation for many exposures and situations where treatment withholding is not justifiable.
- Participant adherence and crossover between arms can dilute the estimated treatment effect in ITT analyses.
- Short follow-up windows may miss delayed adverse events or long-term efficacy differences.
Frequently asked
What is the difference between a randomized trial and a quasi-experimental study?
A true RCT uses random allocation — every eligible participant has a known, chance-based probability of entering each arm. A quasi-experimental study uses non-random assignment rules (alternating allocation, cut-off scores, historical controls) that can reintroduce systematic differences between groups. Quasi-experimental designs are useful when randomisation is infeasible but they do not provide the same causal guarantee.
What does intention-to-treat mean and why does it matter?
Intention-to-treat (ITT) means analysing all randomised participants in the group they were assigned to, regardless of whether they completed the treatment or switched arms. This preserves the balance achieved by randomisation. Excluding non-adherent participants in a per-protocol analysis introduces selection bias because adherence is often related to prognosis, and it typically overestimates efficacy.
How many participants do I need?
Sample size depends on the expected effect size (from pilot data or the literature), the desired statistical power (usually 80–90%), the significance threshold (usually 0.05), and the anticipated dropout rate. There is no universal minimum. A properly powered superiority trial detecting a clinically meaningful difference may need hundreds or even thousands of participants per arm; an equivalence or non-inferiority trial typically requires a larger sample than a superiority trial.
Is blinding always required in an RCT?
Blinding is strongly preferred because it eliminates performance bias (participants changing behaviour based on group knowledge) and detection bias (assessors rating outcomes differently). However, some interventions cannot be masked (e.g., surgery vs. physiotherapy). In open-label trials, using objective, independently adjudicated primary endpoints partially compensates for the absence of blinding.
Should I pre-register my RCT?
Yes. Pre-registration in a public registry (ClinicalTrials.gov, ISRCTN, WHO ICTRP) before enrolment begins is an ethical requirement in most jurisdictions and is expected by journals following ICMJE guidelines. It locks the primary endpoint and analysis plan, preventing post-hoc outcome switching, and allows readers and reviewers to compare what was planned versus what was reported.
Sources
- Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385
- Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332. DOI: 10.1136/bmj.c332 ↗
How to cite this page
ScholarGate. (2026, June 3). Randomized Controlled Trial. ScholarGate. https://scholargate.app/en/epidemiology/randomized-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Case-control studyEpidemiology↔ compare
- Cohort StudyEpidemiology↔ compare
- Cross-sectional epidemiological studyEpidemiology↔ compare
- Phase II clinical trialEpidemiology↔ compare
- Phase III clinical trialEpidemiology↔ compare
- Survival AnalysisResearch Statistics↔ compare